Discovery of 5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole-2-carboxamide derivatives as novel anti-cancer agents targeting Nur77

Eur J Med Chem. 2022 Dec 15:244:114849. doi: 10.1016/j.ejmech.2022.114849. Epub 2022 Oct 14.

Abstract

Encouraged by our previous findings and in continuation of our ongoing study project in designing and synthesis of novel Nur77-targeting anti-cancer agents, a series of 5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole-2-carboxamide derivatives were designed, synthesized and biologically evaluated as potent Nur77 modulators. Among synthesized compounds, 8b maintained good potency against different liver cancer cell lines and other types of cancer cell lines while exhibiting lower toxicity than the positive compound celastrol. Moreover, 8b displayed excellent Nur77-binding activity, superior to the lead compound 10g and comparable to the reference compound celastrol. The cytotoxic action of 8b towards cancer cells was associated with its induction of Nur77-mitochondrial targeting and Nur77-dependent apoptosis. Notably, 8b has good in vivo safety and anti-hepatocellular carcinoma (HCC) activity. Altogether, this study reveals that 8b is a novel Nur77 modulator with great promise for further research.

Keywords: Anticancer activity; Apoptosis; Indole derivatives; Nur77 ligand.

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Apoptosis / drug effects
  • Carcinoma, Hepatocellular* / drug therapy
  • Humans
  • Indoles* / chemistry
  • Indoles* / pharmacology
  • Indoles* / therapeutic use
  • Liver Neoplasms* / drug therapy
  • Molecular Targeted Therapy
  • Nuclear Receptor Subfamily 4, Group A, Member 1* / antagonists & inhibitors
  • Pentacyclic Triterpenes* / chemistry
  • Pentacyclic Triterpenes* / pharmacology
  • Pentacyclic Triterpenes* / therapeutic use
  • Structure-Activity Relationship

Substances

  • Antineoplastic Agents
  • celastrol
  • Indoles
  • Pentacyclic Triterpenes
  • NR4A1 protein, human
  • Nuclear Receptor Subfamily 4, Group A, Member 1